Why the study?
Does pharmacological therapy prevent disease progression and improve prognosis in patients with valvular heart disease?
Does pharmacological therapy prevent disease progression and improve prognosis in patients with valvular heart disease?
This review highlights that while medical therapy can manage symptoms and comorbidities in valvular heart disease, it does not definitively halt disease progression, underscoring the eventual need for mechanical or surgical intervention.
Drug therapy remains adjunctive in chronic valvular disease; leaves open targeted regimens to modify progression.
弁膜症は進行性の疾患である．したがって，外科的治療の適応ではない心臓弁膜症の内科的治療の目標は，弁の障害およびその障害による心機能障害の進展を予防し，外科的治療のタイミングまでADL（activities of daily living）や予後を改善することにある．慢性の各弁膜症において，確立した薬物治療はほとんどないといっても過言ではない．動物実験のデータや臨床データを整理して，各弁膜症の現時点での薬物治療の有用性と限界性について言及する．
No takes yet. Share an insight, caveat, or question.
Yoshio Yasumura (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: